NRIX - What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday? | Benzinga
Sunday, Nurix Therapeutics Inc (NASDAQ:NRIX) announced the presentation of updated clinical data for NX-5948, an orally bioavailable degrader of Bruton’s tyrosine kinase (BTK).
BTK inhibitors have become a major commercial class, with drugs such as BeiGene Inc’s (NASDAQ:BGNE) Brukinsa (Zanubrutinib), Eli Lilly And Co’s (NYSE:LLY) Jaypirca (Pirtobrutinib), Johnson & Johnson’s (NYSE:JNJ) Imbruvica (Ibrutinib), and AstraZeneca Plc’s (NASDAQ:AZN) Calquence (Acalabrutinib).
NX-5948 is being evaluated in an ongoing Phase 1a/b trial in adults with relapsed or refractory B-cell malignancies, including CLL and non-Hodgkin lymphoma (NHL).
The data presented at EHA include safety findings for all patients in the Phase 1a dose escalation study regardless of diagnosis (n=79) and efficacy findings for those patients ...